Pre-existing inflammatory disease predicts cutaneous immunotherapy toxicity development: A multi-institutional cohort study

Guihong Wan; Nga Nguyen; Bonnie W Leung; Hannah Rashdan; Kimberly Tang; Katie Roster; Michael R Collier; Pearl O Ugwu-Dike; Neel S Raval; Nora A Alexander; Ruple Jairath; Jordan Phillipps; Munachimso Amadife; Shijia Zhang; Alexander Gusev; Steven T Chen; Kerry L Reynolds; Nicole R LeBoeuf; Shawn G Kwatra; Yevgeniy R Semenov

doi:10.1016/j.jaad.2023.09.082

Pre-existing inflammatory disease predicts cutaneous immunotherapy toxicity development: A multi-institutional cohort study

J Am Acad Dermatol. 2024 Feb;90(2):418-420. doi: 10.1016/j.jaad.2023.09.082. Epub 2023 Oct 13.

Authors

Guihong Wan¹, Nga Nguyen², Bonnie W Leung², Hannah Rashdan², Kimberly Tang², Katie Roster², Michael R Collier², Pearl O Ugwu-Dike², Neel S Raval², Nora A Alexander², Ruple Jairath², Jordan Phillipps², Munachimso Amadife², Shijia Zhang², Alexander Gusev³, Steven T Chen², Kerry L Reynolds⁴, Nicole R LeBoeuf⁵, Shawn G Kwatra⁶, Yevgeniy R Semenov⁷

Affiliations

¹ Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Department of Dermatology, Harvard Medical School, Boston, Massachusetts.
² Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
³ Department of Medicine, Dana Farber Cancer Institute, Boston, Massachusetts.
⁴ Division of Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
⁵ Department of Dermatology, Dana Farber Cancer Institute, Boston, Massachusetts.
⁶ Department of Dermatology, Johns Hopkins University, Baltimore, Maryland.
⁷ Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Department of Dermatology, Harvard Medical School, Boston, Massachusetts. Electronic address: ysemenov@mgh.harvard.edu.

PMID: 37838257
PMCID: PMC10842377 (available on 2025-02-01)
DOI: 10.1016/j.jaad.2023.09.082

No abstract available

Keywords: autoimmunity; cutaneous adverse reactions; cutaneous immune-related adverse events; immune checkpoint inhibitor; immunotherapy; oncodermatology; pre-existing inflammatory disease.

Publication types

Multicenter Study

MeSH terms

Antibodies, Monoclonal
Antineoplastic Agents, Immunological*
Cohort Studies
Humans
Immunotherapy
Neoplasms*
Skin Diseases*

Substances

Antibodies, Monoclonal
Antineoplastic Agents, Immunological

Publication types

MeSH terms

Substances

Grants and funding